Search clinical trials for: BLU-263

Total 2416 results

Blueprint Medicines Corporation

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis | Monoclonal Mast Cell Activation Syndrome

United States, Spain, Australia, France, Netherlands, Switzerland, Norway, United Kingdom, Austria, Belgium, Germany, Italy, Portugal
Northwestern University
T-Cellerate LLC

Completed

Blue Light Phototherapy

Psoriasis Vulgaris | Grover's Disease

United States
Blueprint Medicines Corporation

Recruiting

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE)

Advanced Systemic Mastocytosis

United States, Norway, Netherlands, Belgium, Germany, France, Spain
Columbia University
National Institute on Aging (NIA)

Active, not recruiting

The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS

Insomnia | Sleep Disturbance | Acute Coronary Syndrome

United States
Shanghai Ninth People's Hospital Affiliated to...

Not yet recruiting

Effect of Fixture Thread Depth on Accuracy of Immediate Implant Placement Using Dynamic Navigation

Tooth Loss | Partial-edentulism
DUSA Pharmaceuticals, Inc.

Completed

Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

Actinic Keratosis

United States
Affiliated Hospital to Academy of Military Medical...

Unknown

Linked Color Imaging/Magnifying Blue Laser Imaging vs. White Light for Adenomas and Serrated Lesions in Proximal Colon

Colon Cancer

China
Fontem US LLC

Active, not recruiting

Nicotine Uptake and Abuse Liability Assessments of 5 Blu Disposable Electronic Cigarettes in Comparison to a Combustible Cigarette

Healthy Volunteers

United States
Medical Dermatology Specialists
DUSA Pharmaceuticals, Inc.

Completed

DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

Actinic Keratosis | Skin Cancer | Non-melanoma Skin Cancer | Sun Damaged Skin

United States
Bellus Health Inc. - a GSK company

Recruiting

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

Healthy | Cough

United Kingdom
Nova Southeastern University

Terminated

Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris

Acne Vulgaris | Acne

United States
Northwestern University

Active, not recruiting

Photodynamic Therapy Incubation Times for Actinic Keratosis

Actinic Keratoses

United States
Valduce Hospital

Completed

BLI (Blue Light Imaging) for the Histological Characterization of Colorectal Polyps

Adenoma Colon

Italy
Blueprint Medicines Corporation

Completed

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

Healthy Volunteers

United States
The Center for Clinical and Cosmetic Research
Sun Pharmaceutical Industries Limited

Recruiting

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

Facial Cutaneous Squamous Cell Carcinoma in Situ

United States
Rogers Sciences Inc.

Unknown

A Feasibility Study of a Novel Phototherapy System for the Management of Acute Burns

Burn Wound

United States
Shanghai Jiao Tong University School of Medicine

Unknown

Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL

Lymphoblastic Leukemia, Acute, Adult

China
Bellus Health Inc. - a GSK company

Completed

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

Healthy

United Kingdom
Zimmer Biomet

Terminated

Clinical Outcomes in Patients Treated With SternaLock Blu (SECURE)

Coronary Artery Disease | Heart Valve Diseases | Cardiac Surgical Procedures

United States
Gilead Sciences

Completed

Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Blueprint Medicines Corporation

Available

Expanded Access Program for Avapritinib

Solid Tumors
Blueprint Medicines Corporation

Active, not recruiting

Study for Patients Previously Treated in Avapritinib Clinical Trials

Gastrointestinal Stromal Tumors

France
Bellus Health Inc

Completed

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (SOOTHE)

Refractory Chronic Cough

United States, Germany, Canada, Czechia, Hungary, Poland, United Kingdom
Blueprint Medicines Corporation

Approved for marketing

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST
Bellus Health Inc. - a GSK company

Recruiting

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Refractory Chronic Cough

Korea, Republic of, United States, Taiwan, Australia, New Zealand, Czechia, United Kingdom, Germany, Slovakia, India
Blueprint Medicines Corporation

Recruiting

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

CNS Tumor | Solid Tumor, Unspecified, Child | Relapsed Solid Neoplasm

United States, Korea, Republic of, United Kingdom, France, Canada, Australia, Austria, Germany, Italy
Bellus Health Inc

Completed

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

Healthy

United Kingdom
Bellus Health Inc

Terminated

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough (RELIEF)

Chronic Refractory Cough

United States, United Kingdom
Bellus Health Inc. - a GSK company

Recruiting

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

Refractory Chronic Cough

United States, Canada, Israel, Spain, Belgium, United Kingdom, South Africa, Argentina, Netherlands, Hungary, Colombia, Turkey, Poland, France, India
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

China
Bellus Health Inc

Completed

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (BLUEPRINT)

Atopic Dermatitis | Chronic Pruritus

United States, Canada
Bellus Health Inc

Completed

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

Cough

Canada
Shanghai Jiao Tong University School of Medicine

Completed

Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

Relapse Rate After Allo-HSCT

China
University of California, San Francisco

Completed

Daylight Photodynamic Therapy for Actinic Keratosis

Actinic Keratoses

United States
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
Dermatology, Laser & Vein Specialists of the Carolinas

Completed

Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times

Actinic Keratoses

United States
Shanghai Jiao Tong University School of Medicine

Recruiting

Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

Lymphoid Neoplasm

China
Blueprint Medicines Corporation

Completed

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

China, Korea, Republic of, Taiwan, Hong Kong, United Kingdom, United States, France, Spain, Switzerland, Singapore, Germany, Italy
DUSA Pharmaceuticals, Inc.

Completed

Twelve Month Follow-Up of CP0108

Actinic Keratosis

United States
Edward Maytin, MD, PhD
DUSA Pharmaceuticals, Inc.

Completed

Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome

United States
DUSA Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

Actinic Keratosis

United States
National University of Malaysia

Unknown

Minimizing Pain Experience In Trigger Finger Steroid Injection.

Trigger Finger

Malaysia
Shanghai Jiao Tong University School of Medicine

Completed

Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies

Lymphoid Malignancies

China
GenMont Biotech Incorporation

Completed

Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients

Type 2 Diabetes

Taiwan
University of Maryland, Baltimore
National Center for Advancing Translational Sciences (NCATS); University of...

Completed

Adjunct VR Pain Management in Acute Brain Injury

Trauma | Traumatic Brain Injury | Pain, Acute | Headaches Posttraumatic

United States
DUSA Pharmaceuticals, Inc.

Completed

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

Keratosis, Actinic

United States
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center

Completed

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Stomatitis | Malignant Neoplasm | Oral Pain

United States
DUSA Pharmaceuticals, Inc.

Completed

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

Keratosis, Actinic

United States
Centre Francois Baclesse
ARCAGY/ GINECO GROUP; French Cancer Research Hospital Program

Completed

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer (MONAVI-1)

Platinum-resistant or Refractory Ovarian Cancer

France

Search clinical trials for: BLU-263

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations